Shareholders Approve Zalm Therapeutics Share Issue – Set Stage to Accelerate Market Entry and Expand Patient Choice

Rua Bioscience shareholders have overwhelmingly approved the purchase of Zalm, throwing further shareholder weight behind the company’s bid to become New Zealand’s premier medicinal cannabis company.